ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: FR-PO264

Evaluation of the Efficacy of CKD Support Decision-Making Application: How It Changes Home Blood Pressure and Kidney Functions

Session Information

Category: CKD (Non-Dialysis)

  • 1902 CKD (Non-Dialysis): Clinical, Outcomes, and Trials


  • Kosaka, Shiho, Tokyo Medical and Dental University, Tokyo, Japan
  • Hoshino, Junichi, Toranomon Hospital, Tokyo, Japan
  • Ubara, Yoshifumi, Toranomon Hospital, Tokyo, Japan
  • Hamada, Masami, Nagoya university, Nagoya, Japan
  • Yamanouchi, Masayuki, Toranomon Hospital, Tokyo, Japan
  • Sekine, Akinari, Toranomon Hospital, Tokyo, Japan
  • Sumida, Keiichi, Nephrology Center, Toranomon Hospital Kajigaya, Kawasaki, KANAGAWA, Japan

Disease management in patients with chronic kidney disease (CKD) is complicated. Appropriate information provision and daily self-monitoring of parameters such as blood pressure are required. Therefore, this study aimed to evaluate how a chronic kidney disease support decision-making application (CKD-SDM) app in patients with CKD affects the blood pressure, kidney functions, and disease-management knowledge at home.


This study was a randomized, controlled trial involving 54 patients with stage 3, 4, or 5 non-dialysis CKD. The intervention group was provided with a tablet equipped with the CKD-SDM app. An automated sphygmomanometer for home blood pressure monitoring (HBPM) was used in both groups for 8 weeks. The primary outcome measure is change in HBPM data from baseline to 8 weeks. Secondary outcomes are changes in renal functions and self-management knowledge level on CKD.


The mean (SD) age, eGFR, and HBPM (morning and evening) of participants were 70.7±11.0 years, 37.0±14.4 ml/min per 1.73 m2, and 133.7±11.5/78.3±8.9 and 130.5±13.4/76.0±8.9 mmHg, respectively. No significant differences between groups were observed at baseline. After 8 weeks, HBPM reduction in both groups were -5.8/-1.5 vs. -3.1/-0.7 mmHg in the morning and -6.1/-3.3 vs. -4.0/-1.5 mmHg in the evening, with no significant differences between the two groups. In the female intervention group, the morning systolic blood pressure (SBP) difference significantly decreased, -7.7 vs. -2.6 mmHg (p<0.05). All kidney functions were not significantly different. Similarly, the self-management knowledge level on CKD was not significantly improved in the intervention group.


Eight weeks of intervention with CKD-SDM app did not reduce the overall HBPM, despite the improved SBP observed in the female intervention group. In the future, we have to plan larger and long-term studies to evaluate HBPM reduction and kidney functions in patients with CKD.
Trial Registration: This study is registered in the UMIN Clinical Trial Registry (000025792).


  • Government Support - Non-U.S.